TB006 Expanded Access (EA) Compassionate Use
- Conditions
- Alzheimer Disease
- Registration Number
- NCT05959239
- Lead Sponsor
- TrueBinding, Inc.
- Brief Summary
This is an open-label, expanded access, compassionate use treatment protocol of TB006 treatment in participants who meet clinical diagnostic criteria for Alzheimer's disease (AD). Participants will receive TB006 at a dose of 4,000 milligrams (mg) intravenous (IV) over 1 hour every 28 days ± 5 days.
- Detailed Description
A participant's physician who is interested in participating in this program will need to go to the company's website for further information and application forms.
Recruitment & Eligibility
- Status
- AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method